For the twelve months ended Sep 30, 2026, ANI Pharmaceuticals Inc. reported $1.04B of revenue and $116.84M of net income.
ANIP revenue was $290.78M in fiscal Q3 2026 (ended Sep 30, 2026), up 27.6% from a year earlier and up 9.3% from the prior quarter. For the full fiscal 2025 it was $883.37M, up 43.8% from fiscal 2024. Compound annual growth was +33.5% over 5 years and +27.7% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.
ANIP net income was $35.15M in fiscal Q3 2026 (ended Sep 30, 2026), up 32.1% from a year earlier and up 42.2% from the prior quarter. For the full fiscal 2025 it was $78.34M, compared with -$18.52M in fiscal 2024. Compound annual growth was +17.7% over 10 years. Fiscal 2025 is the highest of the 15 fiscal years on file.
ANIP diluted EPS was $1.51 in fiscal Q3 2026 (ended Sep 30, 2026), up 33.6% from a year earlier and up 43.8% from the prior quarter. For the full fiscal 2025 it was $3.32, compared with -$1.04 in fiscal 2024. Compound annual growth was +9.7% over 10 years.
ANIP free cash flow was $70.28M in fiscal Q3 2026 (ended Sep 30, 2026), up 85.2% from a year earlier and up 31.1% from the prior quarter. For the full fiscal 2025 it was $171.39M, up 258.7% from fiscal 2024. Compound annual growth was +79.8% over 5 years and +27.5% over 10 years. Fiscal 2025 is the highest of the 15 fiscal years on file.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M | $208.47M | $206.55M | $201.58M | $176.84M | $128.62M |
| Cost of revenue | - | - | - | - | - | $87.16M | $63.15M | $73.02M | $79.03M | $48.78M |
| Gross profit | - | - | - | - | - | $121.32M | $143.39M | $128.55M | $97.81M | $79.84M |
| Research and development | $51.66M | $44.58M | $34.29M | $22.32M | $11.37M | $16.00M | $19.81M | $15.39M | $9.07M | $2.91M |
| Selling, general and admin | $317.75M | $249.64M | $161.70M | $124.04M | $84.29M | $64.99M | $55.84M | $44.06M | $31.58M | $27.83M |
| Operating income | $111.09M | $584.0K | $46.97M | -$35.28M | -$39.79M | -$16.02M | $16.35M | $35.36M | $28.33M | $20.08M |
| Pre-tax income | $95.79M | -$22.21M | $19.87M | -$62.66M | -$56.06M | -$25.96M | $3.16M | $20.05M | $16.35M | $8.68M |
| Income tax | $17.45M | -$3.69M | $1.09M | -$14.77M | -$13.46M | -$3.41M | -$2.94M | $4.56M | $17.43M | $4.74M |
| Net income | $78.34M | -$18.52M | $18.78M | -$47.90M | -$42.60M | -$22.55M | $6.09M | $15.49M | -$1.08M | $3.93M |
| EPS, basic | $3.50 | -$1.04 | $0.86 | -$3.05 | -$3.40 | -$1.88 | $0.51 | $1.31 | -$0.09 | $0.34 |
| EPS, diluted | $3.32 | -$1.04 | $0.85 | -$3.05 | -$3.40 | -$1.88 | $0.50 | $1.30 | -$0.09 | $0.34 |
| Diluted shares | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M | 12.0M | 12.0M | 11.8M | 11.5M | 11.6M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $285.58M | $144.86M | $221.12M | $48.23M | $100.30M | $7.86M | $62.33M | $43.01M | $31.14M | $27.36M |
| Receivables | $281.08M | $221.73M | $162.08M | $165.44M | $128.53M | $95.79M | $72.13M | $64.84M | $58.79M | $45.90M |
| Inventory | $143.07M | $136.78M | $111.20M | $105.36M | $81.69M | $60.80M | $48.16M | $40.50M | $37.73M | $26.18M |
| Current assets | $753.12M | $528.46M | $519.82M | $344.26M | $321.77M | $170.32M | $187.69M | $152.88M | $131.60M | $103.01M |
| Goodwill | $62.48M | $59.99M | $28.22M | $28.22M | $27.89M | $3.58M | $3.58M | $3.58M | $1.84M | $1.84M |
| Total assets | $1.44B | $1.28B | $904.42M | $760.09M | $771.60M | $461.19M | $456.79M | $430.60M | $412.14M | $322.86M |
| Current liabilities | $278.11M | $194.45M | $145.48M | $99.44M | $87.54M | $78.56M | $61.68M | $165.55M | $39.23M | $31.95M |
| Short-term debt | $17.27M | $9.17M | $850.0K | $850.0K | $850.0K | $13.24M | $9.94M | $3.26M | $3.35M | $0 |
| Long-term debt | $291.84M | $309.11M | $284.82M | $285.67M | $286.52M | $172.44M | $175.81M | $67.30M | $69.95M | $0 |
| Total debt | $309.11M | $318.28M | $285.67M | $286.52M | $287.37M | $185.69M | $185.75M | $70.55M | $73.30M | $0 |
| Total liabilities | $899.65M | $855.94M | $446.82M | $421.55M | $412.86M | $265.49M | $244.00M | $233.34M | $237.38M | $153.22M |
| Shareholders' equity | $540.72M | $403.68M | $432.75M | $313.69M | $333.89M | $195.70M | $212.79M | $197.26M | $174.76M | $169.65M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $185.22M | $64.02M | $118.96M | -$31.20M | $3.32M | $15.27M | $45.63M | $67.07M | $39.42M | $27.47M |
| Capital expenditures | $13.84M | $16.24M | $8.87M | $8.88M | $2.56M | $6.13M | $6.63M | $5.74M | $10.37M | $4.57M |
| Free cash flow | $171.39M | $47.78M | $110.09M | -$40.08M | $765.0K | $9.13M | $39.00M | $61.33M | $29.05M | $22.91M |
| Investing cash flow | -$34.32M | -$404.72M | -$18.51M | -$15.74M | -$105.48M | -$68.32M | -$27.55M | -$27.38M | -$107.99M | -$149.06M |
| Financing cash flow | -$9.94M | $264.94M | $67.44M | -$5.13M | $194.59M | -$1.44M | $1.25M | -$27.82M | $72.36M | -$729.0K |
| Dividends paid | $1.16M | $1.63M | $1.63M | $1.63M | $190.0K | $0 | $0 | - | - | - |
| Share repurchases | $12.21M | $10.96M | $4.99M | $1.96M | $890.0K | $1.52M | $1.03M | $0 | $0 | $2.50M |
| Stock-based compensation | $37.93M | $29.34M | $20.65M | $14.60M | $10.49M | $12.94M | $9.22M | $6.78M | $6.09M | $6.07M |
| Depreciation and amortization | $91.42M | $67.73M | $59.79M | $56.97M | $47.25M | $44.64M | $44.61M | $33.74M | $27.93M | $22.34M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 43.8% | 26.2% | 53.9% | 46.4% | 3.7% | 0.9% | 2.5% | 14.0% | 37.5% | 68.5% |
| Net income growth, YoY | - | - | - | - | - | - | -60.7% | - | - | -74.4% |
| EPS growth, YoY | - | - | - | - | - | - | -61.5% | - | - | -74.2% |
| Gross margin | - | - | - | - | - | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating margin | 12.6% | 0.1% | 9.6% | -11.2% | -18.4% | -7.7% | 7.9% | 17.5% | 16.0% | 15.6% |
| Net margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% |
| Free cash flow margin | 19.4% | 7.8% | 22.6% | -12.7% | 0.4% | 4.4% | 18.9% | 30.4% | 16.4% | 17.8% |
| Return on equity | 14.5% | -4.6% | 4.3% | -15.3% | -12.8% | -11.5% | 2.9% | 7.9% | -0.6% | 2.3% |
| Return on assets | 5.4% | -1.4% | 2.1% | -6.3% | -5.5% | -4.9% | 1.3% | 3.6% | -0.3% | 1.2% |
| Current ratio | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 |
| Debt to equity | 0.57 | 0.79 | 0.66 | 0.91 | 0.86 | 0.95 | 0.87 | 0.36 | 0.42 | 0.00 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $290.78M | $266.04M | $237.46M | $247.06M | $227.81M | $211.37M | $197.12M | $190.57M | $148.33M | $138.04M | $137.43M | $131.65M |
| Research and development | $13.00M | $14.75M | $10.60M | $12.26M | $12.30M | $16.54M | $10.56M | $16.65M | $10.13M | $7.30M | $10.51M | $9.87M |
| Selling, general and admin | $94.86M | $91.66M | $73.66M | $82.79M | $76.66M | $81.77M | $76.53M | $69.72M | $79.08M | $52.82M | $48.02M | $44.46M |
| Operating income | $52.37M | $40.46M | $38.89M | $34.77M | $36.24M | $13.89M | $26.19M | -$4.38M | -$20.52M | $5.17M | $20.31M | $6.73M |
| Pre-tax income | $49.04M | $37.10M | $40.22M | $31.48M | $33.80M | $10.53M | $19.99M | -$13.76M | -$31.50M | -$2.29M | $25.34M | $947.0K |
| Income tax | $13.89M | $12.39M | $10.73M | $3.99M | $7.18M | $1.98M | $4.31M | -$3.49M | -$7.33M | $0 | $7.13M | -$208.0K |
| Net income | $35.15M | $24.71M | $29.49M | $27.49M | $26.62M | $8.55M | $15.68M | -$10.28M | -$24.17M | -$2.29M | $18.21M | $1.16M |
| EPS, basic | $1.54 | $1.09 | $1.31 | $1.24 | $1.19 | $0.37 | $0.70 | -$0.47 | -$1.27 | -$0.14 | $0.84 | $0.04 |
| EPS, diluted | $1.51 | $1.05 | $1.28 | $1.14 | $1.13 | $0.36 | $0.69 | -$0.45 | -$1.27 | -$0.14 | $0.82 | $0.05 |
| Diluted shares | 21.7M | 21.9M | 21.5M | - | 21.1M | 20.3M | 20.0M | - | 19.4M | 19.3M | 19.4M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $420.76M | $360.21M | $311.18M | $285.58M | $262.61M | $217.83M | $149.80M | $144.86M | $144.98M | $240.11M | $228.60M | $221.12M |
| Receivables | $304.45M | $274.47M | $255.43M | $281.08M | $252.62M | $225.65M | $220.33M | $221.73M | $196.36M | $166.09M | $172.42M | $162.08M |
| Inventory | $136.41M | $143.15M | $143.47M | $143.07M | $146.47M | $138.31M | $137.41M | $136.78M | $148.04M | $125.45M | $113.84M | $111.20M |
| Current assets | $902.82M | $825.43M | $747.08M | $753.12M | $698.40M | $602.63M | $536.29M | $528.46M | $521.30M | $555.46M | $540.56M | $519.82M |
| Goodwill | $62.48M | $62.48M | $62.48M | $62.48M | $62.48M | $60.53M | $60.66M | $59.99M | $60.43M | $28.22M | $28.22M | $28.22M |
| Total assets | $1.57B | $1.49B | $1.42B | $1.44B | $1.41B | $1.34B | $1.29B | $1.28B | $1.29B | $920.75M | $914.52M | $904.42M |
| Current liabilities | $328.72M | $283.65M | $239.51M | $278.11M | $270.56M | $236.84M | $201.81M | $194.45M | $189.93M | $139.98M | $136.89M | $145.48M |
| Short-term debt | $23.36M | $21.33M | $19.30M | $17.27M | $15.24M | $13.22M | $11.19M | $9.17M | $7.15M | $850.0K | $850.0K | $850.0K |
| Long-term debt | $274.31M | $280.15M | $286.00M | $291.84M | $297.68M | $301.48M | $305.29M | $309.11M | $312.92M | $284.39M | $284.61M | $284.82M |
| Total debt | $297.68M | $301.48M | $305.29M | $309.11M | $312.92M | $314.70M | $316.49M | $318.28M | $320.07M | $285.24M | $285.46M | $285.67M |
| Total liabilities | $930.55M | $896.90M | $859.67M | $899.65M | $902.34M | $881.39M | $848.96M | $855.94M | $856.58M | $440.14M | $437.71M | $446.82M |
| Shareholders' equity | $637.11M | $597.21M | $562.30M | $540.72M | $505.82M | $436.76M | $418.62M | $403.68M | $405.95M | $455.76M | $451.96M | $432.75M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $83.79M | $56.67M | $58.38M | $30.37M | $44.05M | $75.81M | $34.99M | $15.86M | $12.47M | $17.41M | $18.27M | $44.74M |
| Capital expenditures | $13.50M | $3.05M | $6.07M | $1.24M | $6.10M | $4.01M | $2.47M | $2.39M | $4.81M | $4.45M | $4.58M | $2.28M |
| Free cash flow | $70.28M | $53.62M | $52.30M | $29.12M | $37.95M | $71.80M | $32.52M | $13.47M | $7.66M | $12.96M | $13.69M | $42.46M |
| Investing cash flow | -$13.50M | -$3.05M | -$11.32M | -$1.40M | -$6.16M | -$6.91M | -$19.85M | -$10.68M | -$398.52M | -$4.45M | $8.93M | -$4.78M |
| Financing cash flow | -$9.83M | -$4.65M | -$21.62M | -$4.64M | $6.34M | -$1.75M | -$9.91M | -$4.91M | $291.03M | -$1.45M | -$19.73M | -$11.92M |
| Dividends paid | $0 | $0 | $0 | $0 | $344.0K | $407.0K | $406.0K | $406.0K | $406.0K | $407.0K | $406.0K | $406.0K |
| Share repurchases | -$13.58M | $813.0K | $19.75M | $12.21M | -$10.55M | $551.0K | $10.00M | $318.0K | $680.0K | $1.30M | $8.66M | $231.0K |
| Stock-based compensation | $11.63M | $11.41M | $10.19M | $9.77M | $9.69M | $9.60M | $8.87M | $7.06M | $7.49M | $7.86M | $6.93M | $5.62M |
| Depreciation and amortization | $19.55M | $19.64M | $20.92M | $22.61M | $22.63M | $23.28M | $22.89M | $22.60M | $15.75M | $14.70M | $14.69M | $15.19M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 27.6% | 25.9% | 20.5% | 29.6% | 53.6% | 53.1% | 43.4% | 44.8% | 12.5% | 18.4% | 28.7% | 39.7% |
| Net income growth, YoY | 32.1% | 189.1% | 88.1% | - | - | - | -13.9% | - | - | - | 1165.3% | - |
| EPS growth, YoY | 33.6% | 191.7% | 85.5% | - | - | - | -15.9% | - | - | - | 1266.7% | - |
| Operating margin | 18.0% | 15.2% | 16.4% | 14.1% | 15.9% | 6.6% | 13.3% | -2.3% | -13.8% | 3.7% | 14.8% | 5.1% |
| Net margin | 12.1% | 9.3% | 12.4% | 11.1% | 11.7% | 4.0% | 8.0% | -5.4% | -16.3% | -1.7% | 13.2% | 0.9% |
| Free cash flow margin | 24.2% | 20.2% | 22.0% | 11.8% | 16.7% | 34.0% | 16.5% | 7.1% | 5.2% | 9.4% | 10.0% | 32.3% |
| Current ratio | 2.75 | 2.91 | 3.12 | 2.71 | 2.58 | 2.54 | 2.66 | 2.72 | 2.74 | 3.97 | 3.95 | 3.57 |
| Debt to equity | 0.47 | 0.50 | 0.54 | 0.57 | 0.62 | 0.72 | 0.76 | 0.79 | 0.79 | 0.63 | 0.63 | 0.66 |
Source: XBRL data ANI Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-6, first reported Feb 28, 2013.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ANIP | $1.04B | +25.9% | $116.84M | 11.2% | $1.54B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |